Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs
The last three decades have seen the biotherapeutic drug market evolve from promising concept to market dominance in a range of clinical indications. This growth has been spurred by the success of established drug classes like monoclonal antibodies, but also by the introduction of biosimilars, and m...
Main Authors: | Tyler C. Vandivort, David B. Horton, Steven B. Johnson |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2020-12-01
|
Series: | Journal of Clinical and Translational Science |
Subjects: | |
Online Access: | https://www.cambridge.org/core/product/identifier/S2059866120004938/type/journal_article |
Similar Items
-
Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity
by: Kathleen P. Pratt
Published: (2018-05-01) -
Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion
by: Yoshiyuki Arata, et al.
Published: (2023-12-01) -
Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies
by: Maria U. Johansson, et al.
Published: (2023-12-01) -
Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
by: Sophie Tourdot, et al.
Published: (2024-12-01) -
Pre-Clinical In-Vitro Studies on Parameters Governing Immune Complex Formation
by: Marie Fichter, et al.
Published: (2022-06-01)